N
KDNY

Natixis’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Natixis’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,352
Closed -$51.9K – 1168
2023
Q2 		$51.9K Buy
+1,352
New +$34.7K ﹤0.01% 841

Natixis's KDNY Position: Q3 2023 in Review

Natixis sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,352 shares — an estimated $51.9K sold.

Natixis first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $51.9K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Natixis reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Natixis sold 1,352 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $51.9K.
  • Natixis first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Natixis's Chinook Therapeutics, Inc. Common Stock position peaked at $51.9K in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Natixis's 13F filing for Q3 2023, filed 14 Nov 2023.